Symbols / BDTX Stock $2.97 -4.19% Black Diamond Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
BDTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Mark A. Velleca M.D., Ph.D.
Exch · Country NMS · United States
Market Cap 170.15M
Enterprise Value 60.28M
Income 22.37M
Sales 70.00M
FCF (ttm) 13.03M
Book/sh 1.96
Cash/sh 2.25
Employees 21
Insider 10d —
IPO Jan 31, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 7.62
Forward P/E -2.88
PEG —
P/S 2.43
P/B 1.51
P/C —
EV/EBITDA 2.98
EV/Sales 0.86
Quick Ratio 8.18
Current Ratio 8.42
Debt/Eq 16.74
LT Debt/Eq —
EPS (ttm) 0.39
EPS next Y -1.03
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-03-16
ROA 9.35%
ROE 22.88%
ROIC —
Gross Margin 100.00%
Oper. Margin 28.39%
Profit Margin 31.95%
Shs Outstand 57.29M
Shs Float 46.25M
Insider Own 0.62%
Instit Own 77.42%
Short Float 13.68%
Short Ratio 8.50
Short Interest 5.47M
52W High 4.94
vs 52W High -39.88%
52W Low 1.46
vs 52W Low 103.42%
Beta 3.39
Impl. Vol. 12.50%
Rel Volume 1.44
Avg Volume 707.05K
Volume 1.02M
Target (mean) $9.71
Tgt Median $10.00
Tgt Low $7.00
Tgt High $14.00
# Analysts 7
Recom Strong_buy
Prev Close $3.10
Price $2.97
Change -4.19%
About

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.71
Mean price target
2. Current target
$2.97
Latest analyst target
3. DCF / Fair value
$4.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.97
Low
$7.00
High
$14.00
Mean
$9.71

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-17 main Wedbush Outperform → Outperform $14
2026-01-16 main Piper Sandler Overweight → Overweight $8
2025-12-04 down Guggenheim Buy → Neutral —
2025-10-01 init Freedom Broker — → Buy $6
2025-09-04 init Guggenheim — → Buy $8
2025-08-11 main HC Wainwright & Co. Buy → Buy $10
2025-03-18 main HC Wainwright & Co. Buy → Buy $12
2025-03-07 main Stifel Buy → Buy $15
2024-11-06 reit HC Wainwright & Co. Buy → Buy $11
2024-10-09 reit HC Wainwright & Co. Buy → Buy $11
2024-10-08 reit Wedbush Outperform → Outperform $16
2024-09-24 reit HC Wainwright & Co. Buy → Buy $11
2024-09-23 main Piper Sandler Overweight → Overweight $15
2024-09-18 reit HC Wainwright & Co. Buy → Buy $11
2024-09-10 reit Wedbush Outperform → Outperform $16
2024-09-04 reit HC Wainwright & Co. Buy → Buy $11
2024-08-07 reit Wedbush Outperform → Outperform $16
2024-07-31 init Raymond James — → Outperform $20
2024-07-03 main Piper Sandler Overweight → Overweight $12
2024-06-07 reit HC Wainwright & Co. Buy → Buy $11
News
RSS: Latest BDTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-20 BEHBAHANI ALI Director — 6,919 $2.15 $14,876
2026-03-20 RAMAN PRAKASH Director — 6,105 $2.15 $13,126
2025-12-12 BEHBAHANI ALI Director — 5,208 $2.76 $14,374
2025-12-12 RAMAN PRAKASH Director — 4,665 $2.76 $12,875
2025-09-19 BEHBAHANI ALI Director — 4,291 $3.35 $14,375
2025-09-19 RAMAN PRAKASH Director — 3,843 $3.35 $12,874
2025-06-20 BEHBAHANI ALI Director — 6,170 $2.33 $14,376
2025-06-20 RAMAN PRAKASH Director — 5,526 $2.33 $12,876
2025-03-21 BEHBAHANI ALI Director — 7,646 $1.88 $14,374
2025-03-21 RAMAN PRAKASH Director — 6,848 $1.88 $12,874
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
70.00
0.00
0.00
0.00
Operating Revenue
70.00
0.00
0.00
0.00
Operating Expense
50.13
-36.37%
78.78
-8.88%
86.46
-6.86%
92.83
Research And Development
33.56
-34.60%
51.31
-13.54%
59.35
-7.89%
64.44
Selling General And Administration
16.57
-39.67%
27.47
+1.32%
27.11
-4.51%
28.39
General And Administrative Expense
16.57
-39.67%
27.47
+1.32%
27.11
-4.51%
28.39
Other Gand A
16.57
-39.67%
27.47
+1.32%
27.11
-4.51%
28.39
Total Expenses
50.13
-36.37%
78.78
-8.88%
86.46
-6.86%
92.83
Operating Income
19.87
+125.22%
-78.78
+8.88%
-86.46
+6.86%
-92.83
Total Operating Income As Reported
12.52
+115.89%
-78.78
+8.88%
-86.46
+6.86%
-92.83
EBITDA
20.20
+125.75%
-78.44
+8.82%
-86.02
+6.82%
-92.32
Normalized EBITDA
27.54
+135.11%
-78.44
+8.82%
-86.02
+9.02%
-94.55
Reconciled Depreciation
0.33
-5.25%
0.34
-21.51%
0.44
-13.98%
0.51
EBIT
19.87
+125.22%
-78.78
+8.88%
-86.46
+6.86%
-92.83
Total Unusual Items
-7.35
0.00
0.00
-100.00%
2.23
Total Unusual Items Excluding Goodwill
-7.35
0.00
0.00
-100.00%
2.23
Special Income Charges
-7.35
0.00
0.00
-100.00%
2.23
Impairment Of Capital Assets
7.35
0.00
—
—
Net Income
22.37
+132.10%
-69.68
+15.48%
-82.44
+9.57%
-91.17
Pretax Income
22.37
+132.10%
-69.68
+15.48%
-82.44
+9.57%
-91.17
Net Non Operating Interest Income Expense
4.06
+86.11%
2.18
+13.41%
1.92
-5.27%
2.03
Interest Expense Non Operating
—
—
—
—
Net Interest Income
4.06
+86.11%
2.18
+13.41%
1.92
-5.27%
2.03
Interest Expense
—
—
—
—
Interest Income Non Operating
4.06
+86.11%
2.18
+13.41%
1.92
-5.27%
2.03
Interest Income
4.06
+86.11%
2.18
+13.41%
1.92
-5.27%
2.03
Other Income Expense
-1.56
-122.59%
6.92
+230.61%
2.09
+662.90%
-0.37
Other Non Operating Income Expenses
5.78
-16.45%
6.92
+230.61%
2.09
+691.53%
-0.35
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
22.37
+132.10%
-69.68
+15.48%
-82.44
+9.57%
-91.17
Net Income From Continuing Operation Net Minority Interest
22.37
+132.10%
-69.68
+15.48%
-82.44
+9.57%
-91.17
Net Income From Continuing And Discontinued Operation
22.37
+132.10%
-69.68
+15.48%
-82.44
+9.57%
-91.17
Net Income Continuous Operations
22.37
+132.10%
-69.68
+15.48%
-82.44
+9.57%
-91.17
Normalized Income
29.71
+142.65%
-69.68
+15.48%
-82.44
+11.73%
-93.40
Net Income Common Stockholders
22.37
+132.10%
-69.68
+15.48%
-82.44
+9.57%
-91.17
Diluted EPS
—
-1.27
+32.45%
-1.88
+25.40%
-2.52
Basic EPS
—
-1.27
+32.45%
-1.88
+25.40%
-2.52
Basic Average Shares
—
55.03
+25.19%
43.95
+21.32%
36.23
Diluted Average Shares
—
55.03
+25.19%
43.95
+21.32%
36.23
Diluted NI Availto Com Stockholders
22.37
+132.10%
-69.68
+15.48%
-82.44
+9.57%
-91.17
Earnings From Equity Interest
—
—
0.00
+100.00%
-2.25
Gain On Sale Of PPE
—
—
0.00
-100.00%
2.23
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
143.01
+16.61%
122.64
-22.66%
158.57
+1.48%
156.25
Current Assets
132.44
+30.90%
101.18
-24.51%
134.03
+4.96%
127.71
Cash Cash Equivalents And Short Term Investments
128.65
+30.51%
98.58
-24.98%
131.40
+7.00%
122.81
Cash And Cash Equivalents
20.99
-42.39%
36.44
-35.19%
56.22
+63.84%
34.31
Other Short Term Investments
107.66
+73.26%
62.14
-17.35%
75.18
-15.04%
88.49
Prepaid Assets
—
—
—
—
Other Current Assets
3.79
+45.64%
2.60
-1.25%
2.63
-46.23%
4.90
Total Non Current Assets
10.57
-50.75%
21.46
-12.51%
24.53
-14.07%
28.55
Net PPE
9.67
-52.60%
20.40
-13.98%
23.71
-13.41%
27.38
Gross PPE
10.90
-49.41%
21.54
-12.12%
24.51
-12.88%
28.13
Accumulated Depreciation
-1.23
-7.53%
-1.14
-42.93%
-0.80
-6.53%
-0.75
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.00
-100.00%
0.02
+0.00%
0.02
-69.09%
0.06
Construction In Progress
—
—
—
0.00
Other Properties
9.30
-51.06%
19.01
-13.52%
21.98
-14.02%
25.56
Leases
1.59
-36.58%
2.51
+0.00%
2.51
+0.00%
2.51
Other Non Current Assets
0.90
-15.54%
1.07
+29.77%
0.82
-29.54%
1.17
Total Liabilities Net Minority Interest
30.80
-21.74%
39.35
-5.92%
41.83
+3.13%
40.56
Current Liabilities
15.73
-23.54%
20.57
+4.72%
19.65
+28.73%
15.26
Payables And Accrued Expenses
12.02
-30.00%
17.17
+3.85%
16.53
+33.12%
12.42
Payables
0.58
-85.55%
4.01
+72.42%
2.32
+23.81%
1.88
Accounts Payable
0.58
-85.55%
4.01
+72.42%
2.32
+23.81%
1.88
Current Accrued Expenses
11.44
-13.09%
13.16
-7.37%
14.21
+34.77%
10.54
Current Debt And Capital Lease Obligation
3.71
+9.08%
3.40
+9.35%
3.11
+9.57%
2.84
Current Capital Lease Obligation
3.71
+9.08%
3.40
+9.35%
3.11
+9.57%
2.84
Total Non Current Liabilities Net Minority Interest
15.07
-19.77%
18.78
-15.34%
22.18
-12.31%
25.30
Long Term Debt And Capital Lease Obligation
15.07
-19.77%
18.78
-15.34%
22.18
-12.31%
25.30
Long Term Capital Lease Obligation
15.07
-19.77%
18.78
-15.34%
22.18
-12.31%
25.30
Stockholders Equity
112.21
+34.73%
83.28
-28.66%
116.74
+0.90%
115.69
Common Stock Equity
112.21
+34.73%
83.28
-28.66%
116.74
+0.90%
115.69
Capital Stock
0.01
+14.29%
0.01
+0.00%
0.01
+40.00%
0.01
Common Stock
0.01
+14.29%
0.01
+0.00%
0.01
+40.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
57.14
+0.87%
56.64
+9.68%
51.65
+41.75%
36.43
Ordinary Shares Number
57.14
+0.87%
56.64
+9.68%
51.65
+41.75%
36.43
Additional Paid In Capital
576.84
+1.14%
570.36
+6.77%
534.19
+18.05%
452.50
Retained Earnings
-464.74
+4.59%
-487.11
-16.69%
-417.43
-24.61%
-334.99
Gains Losses Not Affecting Retained Earnings
0.10
+320.83%
0.02
+188.89%
-0.03
+98.52%
-1.82
Other Equity Adjustments
0.10
+320.83%
0.02
+188.89%
-0.03
+98.52%
-1.82
Total Equity Gross Minority Interest
112.21
+34.73%
83.28
-28.66%
116.74
+0.90%
115.69
Total Capitalization
112.21
+34.73%
83.28
-28.66%
116.74
+0.90%
115.69
Working Capital
116.71
+44.79%
80.60
-29.54%
114.39
+1.73%
112.44
Invested Capital
112.21
+34.73%
83.28
-28.66%
116.74
+0.90%
115.69
Total Debt
18.78
-15.35%
22.19
-12.30%
25.30
-10.10%
28.14
Capital Lease Obligations
18.78
-15.35%
22.19
-12.30%
25.30
-10.10%
28.14
Net Tangible Assets
112.21
+34.73%
83.28
-28.66%
116.74
+0.90%
115.69
Tangible Book Value
112.21
+34.73%
83.28
-28.66%
116.74
+0.90%
115.69
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
29.61
+147.53%
-62.30
+6.62%
-66.72
+21.59%
-85.08
Cash Flow From Continuing Operating Activities
29.61
+147.53%
-62.30
+6.62%
-66.72
+21.59%
-85.08
Net Income From Continuing Operations
22.37
+132.10%
-69.68
+15.48%
-82.44
+9.57%
-91.17
Depreciation Amortization Depletion
0.33
-5.25%
0.34
-21.51%
0.44
-13.98%
0.51
Depreciation
0.33
-5.25%
0.34
-21.51%
0.44
-13.98%
0.51
Depreciation And Amortization
0.33
-5.25%
0.34
-21.51%
0.44
-13.98%
0.51
Other Non Cash Items
3.05
+2.79%
2.97
+5.58%
2.81
+3.08%
2.73
Stock Based Compensation
6.63
-37.63%
10.63
+10.65%
9.60
-21.26%
12.20
Operating Gains Losses
7.25
+7809.57%
-0.09
-126.26%
0.36
+2005.88%
0.02
Gain Loss On Investment Securities
-0.07
—
—
—
Gain Loss On Sale Of PPE
7.32
+7888.30%
-0.09
-126.26%
0.36
+116.03%
-2.23
Change In Working Capital
-8.73
-224.22%
-2.69
-173.03%
3.69
+137.23%
-9.90
Change In Prepaid Assets
-0.35
-1157.58%
0.03
-98.54%
2.27
+122.50%
1.02
Change In Payables And Accrued Expense
-4.84
-622.33%
0.93
-79.56%
4.54
+156.03%
-8.09
Change In Accrued Expense
-1.41
-87.04%
-0.76
-119.20%
3.94
+167.16%
-5.86
Change In Payable
-3.43
-303.68%
1.68
+181.91%
0.60
+126.77%
-2.23
Change In Account Payable
-3.43
-303.68%
1.68
+181.91%
0.60
+126.77%
-2.23
Change In Other Current Assets
0.18
+170.68%
-0.25
0.00
-100.00%
0.02
Change In Other Current Liabilities
-3.71
-9.11%
-3.40
-9.28%
-3.11
-9.61%
-2.84
Investing Cash Flow
-44.91
-364.65%
16.97
+3.81%
16.35
-69.37%
53.37
Cash Flow From Continuing Investing Activities
-44.91
-364.65%
16.97
+3.81%
16.35
-69.37%
53.37
Net PPE Purchase And Sale
0.03
-71.28%
0.09
+51.61%
0.06
+133.88%
-0.18
Purchase Of PPE
—
0.00
+100.00%
-0.03
+82.81%
-0.19
Sale Of PPE
0.03
-71.28%
0.09
-1.05%
0.10
+955.56%
0.01
Capital Expenditure
—
—
-0.03
+82.81%
-0.19
Net Investment Purchase And Sale
-44.93
-366.28%
16.87
+3.62%
16.28
-69.59%
53.55
Purchase Of Investment
-164.03
-33.49%
-122.88
-98.55%
-61.89
-2.90%
-60.14
Sale Of Investment
119.09
-14.78%
139.75
+78.77%
78.17
-31.24%
113.69
Financing Cash Flow
-0.15
-100.57%
25.55
-64.48%
71.93
+40539.55%
0.18
Cash Flow From Continuing Financing Activities
-0.15
-100.57%
25.55
-64.48%
71.93
+40539.55%
0.18
Net Common Stock Issuance
0.00
-100.00%
24.49
-65.91%
71.85
0.00
Proceeds From Stock Option Exercised
-0.15
-113.87%
1.05
+1184.15%
0.08
-53.67%
0.18
Changes In Cash
-15.44
+21.99%
-19.79
-191.78%
21.56
+168.36%
-31.54
Beginning Cash Position
37.26
-34.69%
57.04
+60.76%
35.48
-47.06%
67.02
End Cash Position
21.82
-41.43%
37.26
-34.69%
57.04
+60.76%
35.48
Free Cash Flow
29.61
+147.53%
-62.30
+6.66%
-66.75
+21.72%
-85.27
Amortization Of Securities
-1.28
+66.18%
-3.78
-222.15%
-1.17
-319.03%
0.54
Common Stock Issuance
0.00
-100.00%
24.49
-65.91%
71.85
0.00
Earnings Losses From Equity Investments
—
—
0.00
-100.00%
2.25
Issuance Of Capital Stock
0.00
-100.00%
24.49
-65.91%
71.85
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category